Abstract The prevalence of hearing impairment is estimated as approximately 1 on 1,000 newborn children. To assess a higher mutation detection rate in individuals with hearing loss a three-step mutation screening program consisting of GJB2 in first line, then GJB1, GJB3 and GJB6 (second step) and if tested negative or heterozygote, testing of GJA1, GJB4, SLC26A4 and PJVK (third) was performed. Audiograms were derived from all patients to characterize audiological features of GJB2 mutations especially. In 59 patients (31.3 %) of the 188 probands, the hearing impairment was due to GJB2 mutations, 45 (23.9 %) of these being homozygous for 35delG mutation and 14 (7.4 %) compound heterozygous for GJB2 mutations in the coding region of exon 2 whereas no significant sequence variation was found in exon 1. In 22 (11.7 %) additional patients a single recessive mutation in GJB2, GJB3, GJB6 and SLC26A4 without a second mutation on the other allele was identified, making genetic counseling difficult. Our study showed significant difference in hearing loss degree in the patients with GJB2-mutations. Fortyfive (45.5 %) GJB2-cases were identified in 99 individuals diagnosed with severe to profound hearing loss, 14 (17.7 %) GJB2-cases were identified in 79 individuals with moderate deafness whereas no clear GJB2 mutation was found in 10 patients with mild hearing loss (p \ 0.001). Revealing a high variability of hearing levels in identical genotypes (even intrafamilial), a significant genotypephenotype correlation could not be established. Based on the identified mutations spectrum and frequencies, speaking mostly of GJB2, a step by step screening for mutations can be devised and in addition may lead to a better stratification of patients for specific therapeutical approaches.
Introduction
Hearing loss represents the most common congenital sensory impairment worldwide. Approximately 1 in 1,000 children is born deaf and an additional 1 in 1,000 children develops severe to profound deafness before adulthood [1] . If hearing impairment remains undetected at birth, it will impede speech perception, language and cognitive development of the newborn infant [2] . Early diagnosis is essential to prevent multiple negative outcomes such as limited communication, inadequate social integration and persistent linguistic deficits in infancy and adulthood. The American Academy of Pediatrics recommends that hearing loss in infants has to be detected before 3 months of age with appropriate intervention not later than 6 months of age [3] . Stimulation of the auditory cortex before the age of 6 months is of prime importance for normal development of the auditory tracts. Neonatal screening for permanent childhood hearing impairment is regularly performed by otoacoustic emission (OAE) or auditory brainstem response (ABR) in several countries such as the USA, United Kingdom, Austria and in some federal states of Germany [4] . When parents are confronted with the diagnosis of their child being hearing impaired they will soon ask the physician about the possible causes of the disability and the future outcome in collaboration with educational and genetic counseling.
Hearing loss is an etiologically heterogenous trait with a high variety in clinical manifestation such as age of onset, type, degree, symmetry and possibly existing inheritance pattern [5] . In about 50 % of the cases, environmental factors including prematurity, prenatal and postnatal infections, head trauma, anoxia and pharmacologic ototoxicity are considered to represent the cause of hearing loss with 50 % remaining to be of genetic origin [6, 7] . Hereditary hearing impairment can be subdivided in to syndromic and nonsyndromic forms. The majority of common syndromic forms (hearing loss associated with other clinical findings) is likely to go undiagnosed in the newborn period since hearing impairment is the only symptom [8] . Targeted diagnostic intervention to scan for Usher, Alport, Jervell or Pendred among 400 syndromes linked with deafness and other clinical features classifies 30 % of the hearing loss disorders attributable to genetic causes as syndromic whereas nonsyndromic or isolated hearing loss is believed to account for approximately 70 %. The pattern of inheritance is autosomal recessive in most cases with percentages up to 80 % while 15-20 % of the cases are autosomal-dominant and the remaining 5 % X-linked and rare mitochondrial [9, 10] . Technical advances in genetics have enabled scientists to identify many genes that cause hearing loss. To date, about 180 loci and 89 genes are assumed to be involved in the different types of sensorineural hearing loss [6] . A proportion of more than 28 of the genes associated with non-syndromic, autosomal recessive hereditary hearing loss (DFNB) has already been identified.
A large number of deafness genes encode proteins which are functionally associated with regulation of ionic homeostasis and signal transduction in the inner ear [11] . Disturbance of cochlear fluid homeostasis and affected generation of endocochlear potential are causal for many forms of hearing loss. Given the complexity of auditory transduction and diversity of cochlear structures, it is estimated that at least 1 % of human protein-coding genes is involved in perception of sound [12] .
Despite this significant genetic heterogeneity, up to 50 % of autosomal-recessive nonsyndromic deafness cases are associated with mutations in GJB2, the gene encoding for connexin 26 (Cx26) [1] . Gap junctions are made of connexins, a large family of membrane proteins allowing both ionic and metabolic coupling between adjacent cells, not only in the inner ear, but also in several tissues such as skin, neurons and colon [13, 14] . Immunohistochemical studies of gap junctions, especially connexin 26 demonstrated high expression levels in the lateral cochlear wall and in the organ of Corti [15, 16] . More than 150 different mutations in GJB2 have been reported to date, mainly described in autosomal-recessive and sporadic cases. Notably the 35delG mutation is most frequent in the majority of Caucasian population, representing up to 80 % of all cases of hearing loss associated with GJB2 mutations [17] . According to this dominating occurrence of a single mutation, carrier frequencies of asymptomatic heterozygous individuals are estimated from 1/190 up to 1/30 in several European countries [18] [19] [20] . This deletion of a single guanine nucleotide at position 35 creates a frameshift mutation resulting in a premature stop codon at amino acid position 13 and a non-functional intracellular domain in the protein. A few specific mutations in this gene also account for autosomal dominant nonsyndromic deafness but with low occurrence [21] . Testing for GJB2 is offered and widely-used in patients with congenital hearing impairment in certain countries [22] [23] [24] .
GJB1 (connexin 32), GJB3 (connexin 31) and GJB6 (connexin 30) as major candidate genes causing hearing loss in Germany are also being considered in the genetic analysis. Each gene encodes for a gap junction protein similar to connexin 26. In contrast to more than 150 different sequence changes reported in GJB2, only 7 autosomal recessive mutations have been characterized in GJB6 so far, 5 of them described as large deletions of 150 kb and more. Digenic inheritance involving GJB2 and GJB6 has been reported in affected individuals tested heterozygous for both genes because of cis-effects of the GJB6-deletions on GJB2 gene expression [25, 26] .
Mutations in the gene SLC26A4, responsible for both Pendred syndrome and nonsyndromic hearing loss with enlarged vestibular aqueduct (EVA), appear to be common in Asian populations [27, 28] . Since no reports have provided a systematic study of the prevalence of SLC26A4 gene mutations in German population we considered sequencing of SLC26A4 in a cohort of patients tested negative for GJB1, GJB2, GJB3 and GJB6. Next to SLC26A4, testing for the DFNB59 gene also called Pejvakin (PJVK) was provided as well as testing for GJB4 and GJA1, two genes encoding for connexin 30.3 and connexin 43. Confirmatory mutations were reported for Pejvakin, GJB4 and GJA1 in Turkish and Iranian deafness families leading us to the consideration in which way these genes are involved in hereditary deafness in German individuals [29, 30] .
In order to establish an effective genetic screening program for hearing-impaired children we designed a step diagnosis program consisting of standard genetic screening in GJB2, GJB3, GJB6 and GJB1 by direct sequencing of coding regions in these genes. Concerning GJB6, an additional mutation scan for two gross deletions, del(GJB6-D13S1830) and del(GJB6-D13S1854) was performed to evaluate the possibly coincidence of mutations in GJB6 with GJB2 heterozygote individuals leading to digenic effects as reported previously [26] . A cohort of hearing affected individuals detected wildtype or heterozygous in GJB1, GJB2, GJB3 and GJB6 was scanned for mutations in GJB4, GJA1, SLC26A4 and DFNB59 in a second step. The aim of our study was to highlight the rate of mutations found in patients with hearing impairment in Germany and to convince many otolaryngologists to advise hearing impaired individuals and their parents to the increasingly large role of genetic testing in terms of clinical diagnostics. Given the fact that family planning of parents with hearingimpaired children is to a high degree dependent on the risk of recurrence this study is trying to emphasize the necessity of offering genetic examinations to the parents of children with hearing loss.
Materials and methods

Patients and data recruitment
In order to evaluate the distribution of genetic causes, especially in the genes GJB1, GJB2, GJB3, GJB4, GJB6, GJA1, SLC26A4 and DFNB59, to non-syndromic hearing loss 211 affected patients (100 females and 111 males) from unrelated families were recruited at the institute of otorhinolaryngology at the university hospital Regensburg. All children and their parents, if available, were offered voluntary entrance in this study. Of these, 23 individuals with an apparently clear environmental/infectious or syndromic etiology for their hearing loss were initially excluded for study design as well as patients with middle ear and retrocochlear pathology. In the remaining cohort, 122 of 188 probands were sporadic cases with only one affected individual in family whereas the remaining 66 probands represented multiple cases from families with at least one first-degree relative diagnosed with hearing loss. The age of the patients ranged from 1 to 49 years (mean 13.7 years).
Beside physical examination of the ear, patients were classified by using age-appropriate audiometric test techniques and tympanometry. Otoacoustic emissions were performed due to German newborn hearing screening, furthermore BERA (brainstem evoked response audiometry) on newborns and pure tone audiometric examinations with a diagnostic audiometer in a soundproof room for growing infants and adults [31] . We used air-and boneconduction at 125, 250, 500, 1,000, 2,000, 4,000 and 8,000 Hz for affected participants to identify the grade of hearing loss. BERA was performed at frequencies between 500-1,000, 2,000-3,000 and 6,000-8,000 Hz. The severity of hearing impairment was classified as mild (20-40 dB) , moderate (41-70 dB), severe (71-90 dB) and profound ([90 dB) by the pure tone average (PTA) of the better ear [32] . Differences of 25 dB and more by comparison of scores between 4,000 and 8,000 Hz and scores between 500 and 2,000 Hz were considered decisive for distinction of high and low tone-related hearing impairment. Asymmetric hearing loss was diagnosed with interaural threshold differences of more than 15 dB at 2-octave frequencies [33] . We considered hearing loss to be progressive when hearing levels worsened more than 15 dB in 3 years.
DNA isolation
Venous EDTA-blood samples (4 ml) or buccal cotton swabs for genetic analysis were obtained from all tested individuals and from family members, if required and after informed consent had been given. Genomic DNA was extracted using QIAamp DNA Blood Midi Kit and QIAamp DNA Mini Kit for buccal swabs (Qiagen GmbH, Hilden, Germany). DNA material for control groups was obtained from 150 medical students (average age 23 years) during practical courses at the department of clinical chemistry and laboratory medicine in Regensburg. Students were asked to provide blood samples DNA samples voluntarily after informed consent has been given. None of them exhibited obvious signs of hearing impairment during conversation but no technical measurements such as PTA were performed. In order to abide the principles of respect for persons, medical ethics and justice according to Institutional Review Board guidelines appropriate information was given to participants in our study notably concerning benefits, risks and possible consequences arising from genetic testing issues.
Mutation analysis by direct sequencing
Mutations in GJB2, GJB3, GJB6, GJB1 as well as in SLC26A4, DFNB59, GJA1 and GJB4 were analysed by direct sequencing of the coding region, intron-exon boundaries and in the GJB2 noncoding exon 1 and its splice site by using exon-flanking oligonucleotides. The primers for PCR-amplification and conditions of the cycling used are shown in the supplementary table. The PCR reaction mix contained: 200 lM of each dNTPs, 1.5 mM MgCl 2 and 2.5 U Taq DNA Polymerase (Qiagen GmbH, Hilden, Germany) added to 10 ll 109 PCR Buffer (contains Tris-Cl, KCl, (NH 4 )2SO 4 , pH 8,7) and, if required, 5 ll 59 Q-Solution in a final volume of 100 ll. PCR products were purified from remaining nucleotides and primers with QIAquick PCR purification Kit according to the manufactures's protocol (Qiagen GmbH, Hilden, Germany) and visualized on ethidium bromide-stained 1 % agarose gels. Cycle-sequencing reactions were performed with ABI Big-Dye terminator v3.1 Cycle Sequencing Kit (PE Applied Biosystems, Darmstadt, Germany) and purified with a DyeEx 96 spin kit (Qiagen GmbH, Hilden, Germany). Sequencing reaction products were suspended in formamide solution and bi-directional DNA sequencing was performed on an ABI Prism Genetic Analyzer 3100xl capillary sequencer (PE Applied Biosystems, Darmstadt, Germany) according to the protocol of the manufacturer.
The sequence obtained was aligned to the reference sequences from NCBI interface using SEQUENCHER software (Gene Codes, Ann Arbor, MI, USA). Segregation of the mutations was verified by analysing the parents, if available. All sequence variations were validated by screening mutation databases (HGMD), SNP databases (dbSNP) and Haplotype (HAPMAP)databases. Novel variations that were not present in any of these databases were sequenced in a large number of ethnically matched healthy controls to obtain data about carrier frequencies for eventual differentiation between mutations and single nucleotide polymorphisms.
Concerning GJB6, detection of deletion del(GJB6-D13S1830) and furthermore del(GJB6-D13S1854) was performed by using a specific polymerase chain reaction assay according to the method described by del Castillo et al. [26, 34] which contains an internal primer that is located in the deleted segment of GJB6. Discrimination of homozygous wildtype (333 bp product), homozygous deleted (460 bp respectively 564 bp) and heterozygous alleles (both products) was performed by electrophoresis on 1 % agarose gel and ethidium bromide stained visualization.
Statistical analysis was performed with MedCalc, Version 11.5.0.0, provided by MedCalc Software (Mariakerke, Belgium).
Results
A total of 211 patients were evaluated for testing in genes GJB2, GJB3, GJB6, GJB1 and furthermore for SLC26A4, DFNB59, GJA1 and GJB4.
Of these, 23 individuals with a clear environmental/ infectious or syndromic etiology for their hearing loss (e.g. neonatal meningitis, USHER syndrome, CHARGE syndrome, ear malformation etc.) were initially pre-selected and not referred for evaluation in this study unless other concerns necessitated genetic counseling (i.e. positive family history, heterozygous genotype with undetected mutation on second allele etc.). In some cases, hearing loss is not classically associated with the clinical diagnosis and may have been caused by environmental circumstances, e.g. treatments according to the particular diagnosis. In the remaining cohort, 122 of 188 probands were sporadic cases with only one affected individual in family whereas the remaining 66 probands represented multiple cases from families with at least one first-degree relative diagnosed with hearing loss. The age of the patients ranged from 1 to 49 years (mean 13.7 years).
Clinical data was derived from patients with mild (10), moderate (79), severe bilateral hearing impairment (39) and profound deafness (60) . Figure 1 shows the spectrum of hearing loss seen in our 188 patients. Most probands showed a congenital hearing impairment that is stable and symmetrical without progression. 16 individuals presented progressive deafness, another 31 were diagnosed with asymmetric hearing impairment. Hearing loss was defined as being asymmetrical with more than 15 dB difference between both ears in at least two frequencies. Phenotypic information about the study sample concerning asymmetry, progress and high tone related deafness is also provided in Fig. 1 .
To obtain carrier frequency data, testing of 150 unrelated and unaffected individuals revealed four heterozygous 35delG mutations resulting in a carrier frequency of 2.7 % and a prevalence of 1/37 in our reference population.
This study revealed a total of 18 mutations in 90 patients listed in Tables 1 and 2 whereas the remaining 98 patients showed no disease related or novel mutation in the 4 analyzed genes GJB2, GJB3, GJB6 and GJB1. The spectrum of sequence variations contains 11 missense mutations, 6 frameshift mutations (including small deletions and 
insertions) and 1 in frame three nucleotide deletion.
Referring to a subsequently performed mutation screening in 39 patients tested negative or heterozygous in the genes listed above two different sequence variations were found in SLC26A4, including 1 splicing variation and 1 intronic variant. In addition to this, 22 different single nucleotide polymorphisms described previously in dbSNP database were derived by sequencing analysis (not listed in tables) in patients and controls. Mutations that were linked to nonsyndromic deafness on the Connexin deafness homepage (http://davinci.crg.es/deafness) or HGMD database (http:// www.hgmd.cf.ac.uk/ac/index.php) were all considered to be pathogenic. Sequence variants not described previously in mutation databases and publications with uncertain pathogenic state were checked by comparative evolutionary conservation between Homo sapiens, rhesus, mouse dog, elephant and opossum using BLAT genome Browser (http://genome.ucsc.edu/cgi-bin/hgBlat).
GJB2 results
Referring to the GJB2 gene, the most common mutation in the German population is the c.35delG found in 65 patients in our study resulting in a mutation frequency of 29.2 % (110/376 alleles). 45 patients showed the c.35delG mutation in homozygous state (23.4 %) and 12 were detected compound heterozygous (6.3 %) for 9 different 35delG/ Non-35delG mutations. In 8 patients a single 35delG allele variant (0.53 % each) with no mutation on the second allele was found. Two patients were identified homozygous for Non-35delG mutations (1.1 %). In addition, two more patients discovered single Non-35delG mutations whereas 119 patient showed no sequence variation in the coding region of GJB2 and exon-intron-boundaries. The GJB2 mutation spectrum revealed in this study is listed in Table 3 . Among 69 probands, a total of 13 mutations were identified. We also discovered 3 novel mutations at positions Ala92Trp (1/150 controls), Gly200Ala (1/188 patients) and 7ins60bp (4/188, was found in four family members). Within the Non-35delG/ Non-35delG sequence variation group, the Val37Ile mutation showed up in homozygous state in a study participant.
Genotype-phenotype evaluation was performed relying on the distribution of the classes of hearing impairment in 35delG/35delG and Non-35delG genotype categories as shown in Fig. 2 . First of all, not a single patient classified with mild hearing impairment showed a sequence variation in GJB2. In the present study, a significant variation (Chi square test, p \ 0.001) was found in GJB2 biallelic mutations and hearing loss degree: 14 (15.7 %) of 89 patients with mild to moderate hearing loss were tested positive for GJB2 biallelic mutations in contrast to 45 (45.5 %) of the remaining 99 patients with severe to profound hearing loss. Chi square testing also indicated that homozygous 35delG patients showed significantly a higher degree of hearing impairment than patients with a 35delG/ Non-35delG mutation or biallelic Non-35delG mutations.
Focusing on mutation detection rates and phenotypic constellation between familial and sporadic causes, no significant difference was evaluated, when comparing 35 individuals with affected relatives and 32 individuals without familial hearing impaired background.
Examples for intrafamilial variability were also revealed in our study. The genealogy of family A with two deaf parents and four children of which three had a severe, one a slight hearing impairment is displayed in Fig. 3 . All affected family members displayed the 35delG sequence variation in GJB2 on both alleles. Both parents are diagnosed with severe to profound hearing loss. The three siblings (two boys and one girl) with severe to profound hearing loss received cochlear implants. Interestingly, the remaining female sibling is diagnosed with moderate hearing loss and wears hearing aids. Family B showed nonaffected parents, the father heterozygous for c.7_8ins60bp and c.31del38 on the same allele whereas the mother is heterozygous for 35delG in the GJB2 gene (shown in Fig. 3 ). Each one of the four siblings revealed the same phenotype with the maternal 35delG and the paternal c.7_8ins60bp and c.31del38. The three boys were diagnosed with profound deafness and received cochlear implants. The girl showed mild hearing loss which is compensated with hearing aids. Moreover, three SNPs (not listed in Table 1 ) Val27Ile, Arg127His and Val153Ile, were found in our patients cohort, all of them in heterozygous state. The c.45C[A variant in the noncoding exon 1 of GJB2, referred as a single nucleotide polymorphism [35] was found in heterozygosity in two patients without further sequence variations in any gene tested in the study.
GJB6 results
We performed direct sequencing of the coding exon and exon-intron boundaries for the GJB6 gene in our study. Testing for rather frequent del(GJB6-D13S1830) and del(GJB6-D13S1854) was used on 150 control patients for frequency prediction as this deletion has been described for clinical relevance to digenic inheritance of GJB2/GJB6 in previous studies. None of the control patients was tested heterozygous for both deletions. Afterwards, screening of our patient cohort showed also wildtype alleles. Direct sequencing of GJB6 in our cohort of 188 patients revealed three different heterozygous amino acid changes in six unrelated individuals as shown in Table 3 . None of these sequence variations, which are located in highly conserved regions, was described previously in dbSNP database or found in 150 controls.
Digenic inheritance involving GJB2 and del(GJB6-D13S1830) or del(GJB6-D13S1854) was not detected in our study.
GJB1 and GJB3 results
In GJB3, three amino acid changes, Lys56Gln (2/188), Arg101Gln (1/188) and Arg106His (1/188) were detected in our patient cohort while control testing showed no sequence variation in position c.166A[C, c.302G[A and c.317G[A. Three known SNPs (not displayed in Table 3 [36] [37] [38] . In GJB1 no sequence variation was found in 188 patients and 150 controls.
After testing for GJB1, GJB2, GJB3 and GJB6 in first line, sequencing analysis of SLC26A4, GJA1, GJB4 and PJVK was performed in a cohort of 39 patients tested negative or heterozygous for mutations in the GJB1, GJB2, GJB3 and GJB6 genes.
SLC26A4 results
No exonic sequence variant was shown in 39 patients which were tested negative or heterozygous for mutations in GJB1, GJB2, GJB3 and GJB6 before. The splice site mutation at position c.1001?1G[A (also known as IVS8?1G[A due to old nomenclature) was found heterozygous in two siblings representing 5.13 % (2/39). Further clinical examination of the siblings revealed enlarged vestibular aqueduct in one of them correlating with descriptions in previous studies where persons with EVA were ascertained just by reason of hearing loss [39] . Another intronic mutation was detected in a single allele at position c.1544?9C[T (or IVS13?9C[T in old scientific notation) which remains unclear. Testing of 50 controls showed no sequence variation at this position. A nucleotide exchange from C[G at the same position is noted as significant splicing variant causing Pendred syndrome in HGMD database [40] .
GJA1 and GJB4 results
Two SNPs at position c.758C[T (2/39) and c.1149?4insA (1/39) were identified in GJA1 patients (not listed in Table 3 ).
In GJB4 also two SNPs were detected. Four patients showed a frameshift mutation at position c.154 with deletion of four bases (TGTC) resulting in a stop codon at amino acid position 106. This mutation was found in five patients, one of them in homozygous state, but also heterozygous in 4/50 controls. Secondary to this we detected a missense mutation c.507C[G in four patients, which was also found once in 50 controls. Both variations are classified as polymorphisms in NCBI SNP database to date.
PJVK (DFNB59) results
Five out of 39 patients tested for mutations in PJVK showed a nucleotide exchange from C to G at position 793. Testing of 50 controls determined a count of 13 heterozygous sequence variants at this position representing a frequency of 26 %. We regarded Arg265Gly as polymorphism in accordance to another study [30] and to date, this sequence variation is registered in dbSNP database. In addition to this, another amino acid change (shown in Table 3 ) registered as SNP in NCBI database was detected in two patients and in 1 of 50 controls, all in heterozygous state.
In addition, we performed mutation screening of GJB2, GJB3, GJB6 and GJB1 in the primarily excluded cohort of 23 patients with an apparently clear syndromic or environmental cause of hearing loss. Two individuals diagnosed with unilateral hearing loss revealed a heterozygote 35delG mutation in GJB2. Another patient with neonatal meningitis was detected heterozygous for the c.682-683insA mutation in GJB6.
Discussion
Several studies have demonstrated that mutations in GJB2 play a major role in causing autosomal recessive nonsyndromic hearing loss in most populations worldwide [11, 41, 42] . According to this fact, European and especially German carrier frequencies were determined to be remarkably high with prevalences about 1/50 [18] . Our study revealed a prevalence of 1/37 and frequency of 2.7 %, relatively high compared to other studies of German populations with estimated frequencies between 0.4 and 1.58 % [19, 43] thus expecting high mutation detection rates in GJB2 tested patients with hearing impairment. The 35delG sequence variation represented a total frequency of 29.2 % in our patient population to range within expected limits related to comparable studies [44] [45] [46] .
Overall, in 59 (31.3 %) of 188 tested probands, GJB2 was shown responsible for hearing impairment accounting for 24.6 % (30/122) in sporadic cases of nonsyndromic hearing loss compared to a significant higher level of 43.9 % (29/66) in familial cases. Given the fact that 78.9 % (45/57) of GJB2-caused hearing impairment is related to the 35delG mutation, our results emphasize the importance of testing for GJB2 in the German population, not only in familial but also in sporadic cases.
As it is commonly quoted GJB2 is responsible for up to 50 % of all genetic hearing impairment cases, our relatively low percentage of 31.3 % is likely due to ascertainment bias in the study preparation. Moreover, comparison with other studies and their mutation detection rates is difficult with variability of study design, demographic influences and extent of analyzing methods. In relation to other German studies [45] [46] [47] with an estimated percentage between 6.4 and 16.7 % of patients with biallelic GJB2 mutations our level of 31.3 % is notably higher, leading us to the suggestion that the contribution of GJB2 to nonsyndromic hearing loss is may be a little overrated in German population but still the leading cause for deafness with genetic background.
In addition, eight probands were found to be heterozygous for 35delG mutation without another mutation in GJB2 or another gene tested in our study resulting in a carrier frequency of 4.2 % (8/188) which is nearly twice the carrier frequency of healthy individuals in our study (2.7 %). This raises the suggestion that a second mutation in GJB2 was not detected by sequencing (mutation in promoter region, intronic mutation or splicing site mutation) or that the presence of mutations in other genes not tested in this study is causative for hearing loss. This relative high frequency of monoallelic 35delG mutations has indeed been noticed previously [48] [49] [50] . Referring to promoter defects in GJB2 as a possible explanation for this fact Pollak et al. [48] did not reveal sequence alterations in the promoter region of GJB2 whereas Matos et al.(2007) detected a basal promoter mutation which can abolish the promoter acitivity of GJB2. Alongside, standard PCR amplification of exon 2 for sequencing analysis is unable to detect gross deletions or sequence variations in the promoter site or the transcription regulating regions. Mutations in these regions could explain the high rate of monoallelic patients. Digenic pattern of inheritance could not be proven in our study, especially no GJB2/GJB6 deletion involvement as the del(GJB6-D13S1830) and del(GJB6-D13S1854) were associated to play a certain role in nonsyndromic hearing loss [51] [52] [53] [54] .
The described Val37Ile mutation in GJB2 which was found in homozygous state in a patient is referred in several publications [23, [55] [56] [57] . In accordance to Pollak et al. [55] our homozygous study patient was diagnosed with moderate hearing impairment as Val37Ile is associated with relatively mild hearing impairment and sometimes remains undiagnosed due to reduced penetrance.
Concerning genotype-phenotype correlation of GJB2, especially of the 35delG mutation, some studies have tried to link audiometric shapes with certain mutations for better diagnosis of genetic hearing loss. Hearing impairment caused by homozygous 35delG mutation is reported to be classified widely spread from moderate to profound degree [1, 56, 58, 59] . In the present study, a significant difference (Chi square test, p \ 0,001) was found in GJB2 biallelic mutations and hearing loss degree comparing the mutation detection rate between mild-moderate (15.7 % with biallelic sequence variation) and severe-profound (45.5 % with biallelic sequence variation) affected individuals. This result supports previous published data showing a more severe-profound phenotype occurring in hearing loss with 35delG etiology [51, [58] [59] [60] [61] . As no mutations were detected in patients with mild hearing impairment, our data lead to the assumption that mutation detection is more likely in individuals with severe to profound deafness, but patients with lower degree of hearing impairment should not be excluded from testing for this reason.
It seems difficult to establish a clear correlation between a certain genotype and a specific phenotype which would be very useful in predictive genetic counseling of parents with known mutations running in the family. Referring to the family pedigrees A and B with identical GJB2 mutations running in the family even siblings show variability in specification of hearing impairment although displaying the same genotype. It seems that the clinical phenotype and outcome of individuals, even intrafamilial, is complicated by environmental factors or possibly other genetic factors which may not be associated with hearing loss at first sight.
On research basis, we subsequently performed mutation screening of the 23 individuals which were primarily excluded by reason of syndromic or environmental causes of hearing loss to confirm possible nonsyndromic gene involvement. Interestingly, three individuals showed a gene variation with two of them revealing a heterozygote 35delG mutation in GJB2 and the third one the c.682-683insA mutation in GJB6. Overlooking the high carrier frequency of GJB2 in affected individuals with a missing second mutation on the other allele it is possibly by coincidence, but could also be regarded as a hint that nonsyndromic genes may also be involved in at-first-sight syndromic or environmental causes of hearing loss.
Due to specific expression profiles and possibly interaction of GJB1 and GJB3 in the developing mouse cochlea [62] we tested our study patients for mutations in these two genes to discover their genetic relevance in the German hearing impaired population. Beyond GJB2, no patients were tested homozygous or compound heterozygous in the additional genes, neither in GJB1, GJB3, GJB6 nor in SLC26A4, DFNB59, and GJA1 and GJB4 to solve the diagnostic gap in genetic testing of hearing impaired patients. Single mutations were found in GJB3 (K56Q, R101Q and R106H) and GJB6 (V190A, M203V and 682insA) not annotated in HGMD and SNP database and not reported in publications before. The role of these sequence variations remains unclear as no second mutation was found to establish a causative connection between genotype and phenotype.
Testing for SLC26A4 was performed to predict the contribution of this gene to nonsyndromic hearing loss in German populations. In 39 patients, tested negative for the gap junction protein genes which are more common in German populations, two siblings (2/39) were detected heterozygous for the SLC26A4 splice site mutation c.1001?1G[A which plays a major role in Asian populations with hearing impairment [63] . Splice site mutations in the SLC26A4 gene are associated with enlarged vestibular aqueduct and Mondini dysplasia also in heterozygous state. In accordance with another European study in France [64] we also agree that SLC26A4 is involved in nonsyndromic hearing with enlarged vestibular aqueduct in Caucasian populations and represents a rather frequent cause of nonsyndromic deafness behind GJB2 as the most common one.
Secondary, the IVS13?9C[T sequence variation was previously described as intronic variant [64] but at the same position a nucleotide exchange from C[G on is noted as significant splicing variant in HGMD database causing Pendred syndrome raising the question if a different allele variation at a certain position has the same mutation effect.
Two severe hearing impaired siblings without further clinical significant features for syndromic hearing loss showed a splice site mutation, classified c.1001?1G[A in gene SLC26A4. After genetic testing, clinical checkings evaluated an enlarged vestibular aqueduct (EVA) in one of the siblings, matching with genotype-phenotype correlations performed in previous studies [65] [66] [67] which assume a correlation between the c.1001?1G[A splicing mutation and nonsyndromic hearing impairment with EVA. In analogy to GJB2, a high percentage of patients with simple heterozygosity in SLC26A4 is reported in previous studies, raising the question of the pathogenicity of these monoallelic mutations, especially in patients with EVA. In fact, sequencing analysis using standard PCR is not able to identify gross deletions of complete exons and gene regions required for regulation and translation (e.g. promoter and enhancer region). In the literature, testing of FOXI1 as a transcriptional activator gene of SLC26A4 showed the occurrence of EVA in patients carrying single mutations in both SLC26A4 and FOXI1 [39] supporting the contribution of SLC26A4 in nonsyndromic hearing impaired patients with monoallelic mutations.
An estimated 6-15 % of the nonsyndromic deafness patients in Caucasian populations carry enlarged vestibular aqueducts or Mondini dysplasia [64, 68, 69] . This example underlines the statement that genetic testing for SLC26A4 should also be provided in apparently nonsyndromic hearing impaired people to gain a higher mutation detection rate and to provide further clinical investigation such as scanning for EVA, thyroid malfunction, goitre and perchlorate abnormalities in SLC26A4 mutation positive patients.
The finding of our study reveals that genotype-phenotype correlation in GJB2 and SLC26A4 related deafness is of high variability and should be interpreted cautiously because it is of utmost importance for prognostic information and genetic counseling of affected individuals and their family members. Unless a clear connection between genotype and phenotype cannot be set up, further research is required to provide better counseling to families with affected siblings. Clinical treatment of individuals with hearing loss should be performed in interdisciplinary teamwork including an otolaryngologist with special knowledge in auditory disorders, a clinical geneticist and a speech therapist.
Conclusion
In order to establish an effective genetic screening program for hearing impaired children we designed a step diagnosis program consisting of standard genetic screening in GJB2, GJB3, GJB6 and GJB1 by direct sequencing of coding regions in these genes. A cohort of hearing affected individuals detected wildtype or heterozygous in GJB1, GJB2, GJB3 and GJB6 was scanned for mutations in GJB4, GJA1, SLC26A4 and DFNB59 in a second step.
In our study of German hearing impaired individuals, mutations in GJB2 gene account for 31.3 % (59/188) of the patients with nonsyndromic hearing loss. High variation in mutation rates in other studies is to be caused by less strict selection of study samples such as including people with slight or moderate hearing impairment. In GJB2, the most common mutation 35delG tends to be correlated more often with severe to profound hearing impairment than mild to moderate degree of hearing loss. Hints for digenic inheritance involving GJB2 and GJB6 as described before in publications were not found in the present study. As only two different mutations in SLC26A4 were found in heterozygous state in three patients (3/39 = 7.69 %) we assume that Pendred syndrome accounts only for a small percentage of hearing loss in Caucasian populations. Establishing DFNB59, GJA1 and GJB4 testing in Caucasian populations revealed no sequence variations being regarded etiologic for hearing impairment. Focusing on GJB2 in genetic testing strategy appears to be most effective in mutation detection as the remaining seven genes show low counts of responsibility for nonsyndromic hearing loss in German populations.
The aim of our study was to highlight the rate of mutations found in patients with hearing impairment in Germany and to convince many otolaryngologists to advise hearing impaired individuals and their parents to the increasingly large role of genetic testing in terms of clinical diagnostics. Given the fact that family planning of parents with hearing impaired children is to a high degree dependent on the risk of recurrence this study is trying to emphasize the necessity of offering genetic examinations to the parents of children with hearing loss. In the face of a significant amount of patients with hearing loss and a single mutation in heterozygous state, the aspect of a missing mutation on the other allele should be further investigated.
